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Oncolytic viruses preferentially infect and replicate in cancerous cells, leading to elimination of tumour
populations, while sparing most healthy cells. Here, we study the cell cycle-specific activity of viruses such
as vesicular stomatitis virus (VSV). In spite of its capacity as a robust cytolytic agent,VSV cannot effectively
attack certain tumour cell types during the quiescent, or resting, phase of the cell cycle. In an effort to
understand the interplay between the time course of the cell cycle and the specificity of VSV, we develop
a mathematical model for cycle-specific virus therapeutics. We incorporate the minimum biologically
required time spent in the non-quiescent cell cycle phases using systems of differential equations with
incorporated time delays. Through analysis and simulation of the model, we describe how varying the
minimum cycling time and the parameters that govern viral dynamics affect the stability of the cancer-free
equilibrium, which represents therapeutic success.
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1. Introduction
The efficacy of cancer treatment has improved dramatically in the last decade. However, patients
with certain forms of cancer are still left with limited options for therapy. Many tumours also
remain completely incurable, creating a need for a broader spectrum of therapeutic strategies.
One promising form of treatment is oncolytic virotherapy. This technique employs replication-
competent viral vectors as agents that preferentially attack and proliferate in cancerous cells,
leaving most healthy cells uninjured. The result is the destruction of tumour populations without
appreciable damage to normal tissue. There are many oncolytic viruses which have demonstrated
anti-tumour efficacy, including adenoviruses [14], Coxsackieviruses [1], herpes simplex viruses
[26], measles viruses [11], Newcastle disease virus [22], reoviruses [10], Seneca Valley virus [24],
vaccinia viruses [21], and vesicular stomatitis virus (VSV) [6].
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Mathematical modelling of cancer treatment can illuminate the underlying dynamics of therapy
systems and can lead to more optimal treatment strategies. A wide variety of virotherapy mod-
els have been proposed which consider spatial representation of tumours [13,29,31], multi-scale
effects [20] and stochastic processes [25]. A number of models have been developed and analysed
based on population dynamics of tumour cells subjected to virotherapy treatment [3,15,18,30].
A defining feature of these ordinary differential equation (ODE) models is the compartmental-
ization of uninfected tumour, infected tumour, and free virus populations. The lytic activity of
viral particles is also a fundamental component. Several models have been custom tailored to
certain viruses for the purpose of developing optimal therapy schedules [2,8]. Findings of these
studies have recapitulated that each candidate virus has unique oncolytic dynamics, leading to a
unique treatment plan. Therefore, it remains essential to develop models in order to understand
the therapeutic impact of such dynamics for individual viral vectors.
In this paper, we develop a mathematical model for the cell cycle-specific activity of the
oncolytic VSV therapeutic. VSV is an RNA virus which has demonstrated anti-tumour efficacy
in a large panel of human tumour cell lines, including prostate, breast, cervical, and haematologic
cancers [4]. Importantly, it has oncolytic activity in several tumour cell types that are resistant
to chemotherapy [4]. The efficacy of VSV has been attributed to a defective antiviral interferon
response in tumours, leading to preferential attack and replication in cancerous cells [5].
A distinguishing characteristic of VSV is its inability to replicate in leukemic T-lymphocytes
in the quiescent (resting) phase of the cell cycle known as G0 [19]. This renders quiescent cells
resistant to VSV treatment, while cycling cells remain susceptible. We know of no model of
virotherapy that accounts for cycle specificity of the viral agent; however, models have been
developed for cancer treatment with cycle specific chemotherapy agents [16,28]. These models
compartmentalize the phases of the cell cycle for the study of the therapeutic agent’s action
on cancerous cells throughout the different phases. Delay differential equations (DDE) are then
utilized to account for the minimum biological time course of certain phases.
In a similar fashion to two of the chemotherapy models, Villasana and Radunskaya [28] and
Liu et al. [16], we separate cycling and quiescent cell populations into compartments and account
for the minimum time course of the active phases of the cell cycle. To incorporate virotherapy,
we also separate cycling cells into infected and uninfected compartments and model the viral
lytic cycle, which includes virus-uninfected cell contact and the release of viral particles upon
death of infected cells. Without taking into account the time delay, virotherapy is modelled as in
Bajzer et al. [2]. However, once the minimum time course of the active phases of the cell cycle
are incorporated, the complexities of these virus-cell interactions require a system that includes
an age-structured partial differential equation (PDE). Previous authors have developed models
for chronic myelogenous leukaemia in which age structure accounts for time spent in the cell
cycle [9,23]. Likewise, we utilize age structure to account for the temporal dynamics of the cell
cycle. Figure 1 provides a schematic of our full model.
Close inspection of the models created by Villasana and Radunskaya [28] and Liu et al. [16]
reveals that there is a more correct way to properly account for decay of tumour cells. We modify
the Liu et al. [16] model of tumour growth to properly account for cell death and viral attack
during the delay period. Proper accounting of cell death is achieved through the inclusion of an
additional compartment for cells which have exited G0 and must remain in the non-resting phases
for a minimum time determined by the delay value. However, during this time, cells can still die
and exit the compartment. This important feature of our basic tumour growth model extends to
our full virotherapy model.
In an attempt to uncover the determinants of effective virotherapy treatment with VSV, we
investigate which parameters most significantly impact the stability of equilibria. We also examine
how the length of the time delay and parameter values governing viral dynamics affect the stability
of these steady states. Such analysis elucidates the factors that promote complete remission,
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Figure 1. Compartmental diagram for the full model of virotherapy. Transfer occurs from the quiescent to the
non-quiescent, or susceptible, cell population at rate a1, and susceptible cells begin mitosis at rate a2. Susceptitle cells
remain in a holding state for at least τ units of time. After completing mitosis, two daughter cells enter the quiescent
population. Susceptible cells are infected through contact with the free virus population at rate κV/N and enter the
infected state. Viral reproduction in infected cells, combined with lysis, leads to production of free virions at a rate α.
Although not shown in the diagram, all cell and virus populations, Q, S, Sˆ, I , and V die or decay at rates d1, d2, d3, δ,
and ω, respectively.
limitation of tumour growth, or uncontrolled tumour growth. Additionally, we perform numerical
simulations of the full virotherapy model for additional analysis of fixed points and parameter
interaction.
2. Mathematical model and stability results
We incrementally develop our mathematical model. The first step is the analysis of a simple
two-dimensional ODE model for tumour growth. We then consider a three-dimensional DDE
model for tumour growth and analyse delay effects in the absence of therapy. Following this, we
again exclude the time delay and extend the two-dimensional ODE model to include virotherapy,
resulting in a four-dimensional system of ODEs. Finally, the inclusion of a time delay yields our
complete model: a five-dimensional cycle-specific age-structured model for virotherapy treatment
with VSV.
2.1. The virus-free system
Our model for tumour growth in the absence of therapy contains parameters determining the rates
of cell division, death, and transfer between resting and active states of the cell cycle, and later, the
added delay parameter. The analysis aims to predict how these parameters impact achievement of
a tumour-free state without therapy. These findings will be important for comparative purposes
when analysing our model with therapy.
2.1.1. Non-delay case
We are interested in studying the case where VSV cannot attack tumour cells in the resting phase
known as G0, but can infect cells in all other phases. Therefore, we partition tumour cells into two
populations: Q (quiescent) – volume of cells in the quiescent or resting stage of the cell cycle,
and S (susceptible) – volume of cells in all other phases of the cell cycle, including stages of
growth, DNA synthesis, and mitosis. In the absence of virotherapy treatment and a time delay,
we are left with a simple two-dimensional linear system of ODEs. The asymptotic behaviour of
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any trajectory is either exponential growth or decay to the origin. The conditions for stability
and instability of the cancer-free equilibrium (CFE), (Q, S) = (0, 0), are determined using linear
systems theory. The governing equations are as follows:
Q′(t) = 2a2S − a1Q − d1Q, (1)
S ′(t) = a1Q − a2S − d2S. (2)
Cells leave Q and enter S at a rate of a1. Natural cell death occurs in Q at a rate of d1 and in S at
a rate of d2. After mitosis, two daughter cells emerge from S and enter the the quiescent state, Q;
hence the term 2a2S. Note that it is possible for cells to immediately exit back into S.
The eigenvalues of the corresponding Jacobian matrix about (Q, S) = (0, 0) are
λ1,2 = −(a1 + a2 + d1 + d2) ±
√
(a1 + a2 + d1 + d2)2 − 4(a1(d2 − a2) + d1(a2 + d2))
2
.
Here we know both eigenvalues are always real when all parameters are non-negative, since,
(a1 + a2 + d1 + d2)2 − 4(a1(d2 − a2) + d1(a2 + d2))
= d21 + (a1 + a2 + d2)2 − 2d1(a1 + a2 + d2) + 4a1a2,
and it follows from the Cauchy–Schwarz inequality that
d21 + (a1 + a2 + d2)2 ≥ 2d1(a1 + a2 + d2).
Therefore, if a1(d2 − a2) + d1(a2 + d2) > 0, both eigenvalues are negative and the CFE is stable,
implying that the tumour would naturally be eradicated. Contrarily, if a1(d2 − a2) + d1(a2 +
d2) < 0, then one eigenvalue is positive, the CFE is unstable, and the tumour grows exponentially.
Notice that if either d1 > a1 or d2 > a2 (either compartment has a death rate which dominates
the corresponding rate of transfer within the system), then the CFE is stable. We note that these
results are analogous to those of Villasana and Radunskaya [28].
2.1.2. Delay case
The previous model of exponential tumour growth and death did not fully account for several time-
consuming processes of the cell cycle. In this section, we add a delay which reflects the minimum
time required to complete DNA replication, mitosis, and their requisite metabolic processes. The
duration of these processes varies, but there is a minimum, biologically required amount of time,
τ , to complete them. Studies of a broad array of human solid tumour types revealed that cell cycle
progression lasts 2 days, on average [27]. The model in the previous section did not account for
a minimum time for cycle completion, allowing cells that entered S to immediately exit. In the
following model, we force cells that enter the susceptible state to remain there for at least τ days.
The model equations are
Q′(t) = 2a2 e−d3τ S(t − τ) − a1Q − d1Q, (3)
S ′(t) = a1Q − a2S − d2S, (4)
S¯ ′(t) = a2S − d3S¯ − a2 e−d3τ S(t − τ), (5)
with history functions given by Q(t) = φq(t), S(t) = φs(t) and S¯(t) = φs¯(t), for −τ ≤ t ≤ 0.
The state S¯ represents the volume of susceptible cells which are committed to completing the
necessary biological processes of the active phases of the cell cycle. Notice that Equations (3) and
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(4) do not contain the variable S¯. Here, the compartment S¯ is used only for book-keeping purposes;
that is, to determine the total volume of cells that are susceptible (S + S¯). Our model improves
upon previous models of tumour growth by properly factoring in cell death during the delay
period. As indicated in Liu et al. [16], the model developed by Villasana and Radunskaya [28]
removes cells from interphase at time t based on how many cells there were τ days ago, without
accounting for the amount of these cells that have naturally died since then. This can lead to
solutions that become negative. Additionally, all cells that leave the interphase immediately enter
mitosis, and because natural death is not accounted for, too many cells enter mitosis. The latter
issue remained in the model proposed by Liu et al. [16], where the proper amount of cells is
removed from interphase and positivity of solutions is guaranteed. But, as in the case of Villasana
and Radunskaya [28], death is not accounted for during the delay period, resulting in the passage
of too many cells into mitosis; therefore, tumour populations are, in general, overstated.
To properly account for cell death during the minimum time period in the non-resting phases,
τ , the rate that cells enter Q should be proportional to the amount of cells that were in the S state τ
days ago, multiplied by a factor which represents natural death (exponential decay) at a rate of d3
per day. Thus, the term 2a2S from Equation (1) is replaced by 2a2 e−d3τ S(t − τ). Cells in S leave
at a rate a2 after being in S¯ for the minimum amount of time, τ days, necessary to complete the
non-quiescent phases. Note that we allow cells in S¯ to die at a different rate, d3, than those in S.
It is, however, likely that d2 = d3.
The compartment S¯ does not affect the rate of change of the Q or S populations, but to find the
amount of cells in the susceptible state at any time, we add the amount of cells in S to the amount
of cells in S¯, which is determined by calculating an explicit solution for Equation (5):
S¯(t) = S¯(0) e−d3t + a2 e−d3t
∫ t
t−τ
ed3uS(u) du − a2 e−d3t
∫ 0
−τ
ed3uφs(u) du.
We also assume that cells that are in the holding state before t = −τ , leave before t = 0.
Mathematically, we can do this by setting S¯(0) = a2
∫ 0
−τ e
d3uφs(u) du. In this case
S¯(t) = a2 e−d3t
∫ t
t−τ
ed3uS(u) du. (6)
Furthermore, because we can explicitly solve for S¯ in terms of S, when studying dynamics or
looking for solutions, we can exclude it from the system and only consider Equations (3) and (4).
Theorem 2.1 Assume that φq(t), φs(t) and φs¯(t) are non-negative. Then, solutions of Equations
(3)–(5) are non-negative for t > 0.
Proof We study the time-varying vector field in the Q − S plane. Solutions starting in the first
quadrant become negative by crossing either the Q-axis or the S-axis. Along the positive part of
the Q-axis, S = 0 and S ′(t) > 0. Therefore, the vector field points upward. As such, solutions
cannot cross the positive part of the Q-axis from the first quadrant.
Assume towards a contradiction that a solution crosses the S-axis above the origin into the
second quadrant for some t ∈ [0, τ ). So for some t1 ∈ [0, τ ], the solution is moving to the left,
Q′(t1) < 0, into the second quadrant where S > 0 and Q ≤ 0. But if we assume φs(t) ≥ 0, then
because S(t1 − τ) ≥ 0 and Q(t1) < 0, Q′(t1) must be positive – a contradiction.
At the origin, solutions either remain or become positive, since S has a non-negative history
function. The same is then true for t ∈ [τ, 2τ ]. This process can be carried out ad infinitum,
and Q′(t) will never be negative. Therefore, solutions cannot cross the S-axis and will remain
non-negative for all time. Note that non-negativity of S¯(t) is guaranteed since S(t) remains
non-negative. 
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The system consisting of Equations (3) and (4) is linear, so the only fixed point is (0, 0), barring
linear dependence of coefficients, which does not occur in the general case. The Jacobian is
J =
[−(a1 + d1) 2a2 e−d3τ e−λτ
a1 −(a2 + d2)
]
,
from which we derive the characteristic equation:
P(λ) = 2a1a2 e−d3τ e−λτ − (a1 + d1 + λ)(a2 + d2 + λ) = 0. (7)
We now investigate the stability of the CFE (0, 0), for the system of Equations (3)–(4). Our
main result, given below, describes a condition on τ , which, if achieved, results in a stable CFE.
Theorem 2.2 For any a1, a2, d1, d2, d3 > 0, (Q, S) = (0, 0) is stable when
τ >
1
d3
log
(
2a1a2
(a1 + d1)(a2 + d2)
)
> 0
and unstable when
0 < τ <
1
d3
log
(
2a1a2
(a1 + d1)(a2 + d2)
)
.
Theorem 2.2 shows that for any growth and death rates, there is a τ , given by the condition in
the theorem, for which the tumour would be naturally eliminated. To prove this theorem, we must
first prove the following lemma.
Lemma 2.3 For any a1, a2, d1, d2, d3 > 0, the rightmost eigenvalue derived from the
characteristic equation (7) is real.
Proof The function P(λ) is strictly decreasing for λ > − min(a1 + d1, a2 + d2). Furthermore,
P(− min(a1 + d1, a2 + d2)) > 0 and P(λ) → −∞ as λ → ∞. Hence, P(λ0) = 0 for exactly
one value of λ0 > − min(a1 + d1, a2 + d2).
Suppose λ∗ = λr + iλi is any eigenvalue of Equation (7), where λr, λi ∈ R. Then,
P(λ∗) = 0 ⇒ (a1 + d1 + λr + iλi)(a2 + d2 + λr + iλi) = 2a1a2 e−d3τ e−(λr+iλi )τ .
Taking the magnitudes of both sides of the equation, we obtain
√
((a1 + d1 + λr)2 + λ2i )((a2 + d2 + λr)2 + λ2i ) = 2a1a2 e−d3τ e−λr τ .
Since
(a1 + d1 + λr)(a2 + d2 + λr) ≤
√
((a1 + d1 + λr)2 + λ2i )((a2 + d2 + λr)2 + λ2i ),
it follows that
0 ≤ 2a1a2 e−d3τ e−λr τ − (a1 + d1 + λr)(a2 + d2 + λr),
which indicates that P(λ0) = 0 ≤ P(λr). Since P(λ) is decreasing with respect to λ for λ ≥ λ0,
it follows that Re(λ∗) = λr < λ0. Therefore, the real eigenvalue λ0 is, indeed, the rightmost
eigenvalue. 
Having proved the previous lemma, we prove the following proposition. The theorem
directly follows.
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Proposition 2.4 For any parameters a1, a2, d1, d2, d3 > 0, the CFE (Q, S) = (0, 0) of the
system of Equations (3) and (4) is globally asymptotically stable if
2a1a2 e−d3τ − (a1 + d1)(a2 + d2) < 0,
and unstable if
2a1a2 e−d3τ − (a1 + d1)(a2 + d2) > 0.
Proof Recall from the first line of the proof of Lemma 2.3, that P(λ) is strictly decreasing for
λ > − min(a1 + d1, a2 + d2). Therefore, if
P(0) = 2a1a2 e−d3τ − (a1 + d1)(a2 + d2) < 0,
then there are no non-negative real eigenvalues. By Lemma 2.3, the rightmost eigenvalue of
Equation (7) is real, so all eigenvalues must have negative real parts. Hence, the CFE of system
(3) and (4) is asymptotically stable. Global stability follows, since Equations (3) and (4) is linear.
On the contrary, if
P(0) = 2a1a2 e−d3τ − (a1 + d1)(a2 + d2) > 0,
then there exists a positive real eigenvalue. Therefore, the CFE is unstable. 
We note that, based on the above proposition, in the τ = 0 case, the conditions for stability or
instability of the origin are identical to those for the system of Equations (1) and (2). Given a1,
a2, d1, d2 and d3, it is also possible to determine a threshold delay value, about which stability
switches occur. Our model for tumour growth indicates that lengthening the time spent in the active
phases of the cell cycle can eradicate the tumour. In essence, the delay is reducing the growth rate
by lengthening the doubling time of the tumour population. Many cancer chemotherapy agents
function via similar cell cycle inhibiting effects. By arresting rapidly proliferating cells, such drugs
can both reduce tumour growth rates and stimulate apoptosis due to insufficient metabolic activity.
2.2. The virotherapy system
In this section, we add cell cycle-specific oncolytic virotherapy to the model for tumour growth.
The model will now contain an additional layer of dynamic complexity, resulting from the inclu-
sion of free virus (V ) and infected cell (I ) populations, as well as the presence of a nonlinear,
ratio-dependent contact term. We first consider the system without taking into account the mini-
mum time needed to travel through the cell cycle. We then consider this effect by adding the time
delay through age structure.
2.2.1. Non-delay case
VSV infects susceptible cells and replicates repeatedly, leading to lysis. When lysis occurs, the
viral particles are free to infect other susceptible cells. Previous authors have modelled oncolytic
virus infection with a mass action term, similar to many epidemic models, where the infection
rate is dependent on the amount of susceptible tumour cells and the amount of virions, described
mathematically by κ¯S(t)V (t), where κ¯ is the rate of infection with units day−1 × (cells and
virions)−1 [3,30]. Mass action is an appropriate approximation when the total population of cells
and virions is fairly constant, but it generally assumes that the contact rate grows as the population
of virions and cells grows; that is, the density of the population is proportional to the total amount
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of cells and virions [18]. When density does not change with the amount of cells or virions, it is
more appropriate to use a ratio-dependent transmission term κS(t)V (t)/N(t), where N(t) is the
total amount of cells and virions. κ is equal to the probability of infection per virion contact with a
susceptible cell, times the average number of contacts virions make per day with cells and virions,
and has standard rate units day−1. S(t)/N(t) is the proportion of contacts made with susceptible
cells. The ratio-dependent term is necessary to account for the likelihood that a virion will come
in contact with a susceptible cell, assuming that each virion is equally likely to contact any type
of cell or other virions. Of course, cells are larger than virions, but more individual virions will be
nearby. In addition, even if one or several populations become arbitrarily large, the proportional
infection rate will saturate to κ .
A mathematical advantage of modelling infection with ratio-dependent transmission is that
the virus can affect the stability of the CFE, thereby suggesting that the virus can eliminate the
tumour [18]. Contrarily, mass action dynamics cannot impact the stability of the origin. This
becomes clear by inspecting the linearization of the system about the origin. The mass action
term κ¯S(t)V (t) is represented in the Jacobian by either κ¯S(t) or κ¯V (t). At the origin, both of
these terms are zero.
Using the ratio-dependent contact to describe viral infection, our model becomes
Q′(t) = 2a2S − a1Q − d1Q, (8)
S ′(t) = a1Q − a2S − d2S − κ V S
N
, (9)
I ′(t) = κ V S
N
− δI, (10)
V ′(t) = αI − κ V S
N
− ωV, (11)
where the total of amount of cells and virions, here measured by volume (mm3), changes with
time and is given by N(t) = Q(t) + S(t) + I (t) + V (t).
The Q compartment is unchanged by the virus because the virus cannot infect quiescent cells.
Susceptible cells become infected at a rate of κ per day, exiting S and entering I at a rate of
κV S/N [18]. Infected cells are eliminated at a rate of δ per day by lysis due to viral replication
or by the cytotoxic immune response. Lysis of infected cells releases free viral particles at a rate
of α. When virions infect susceptible cells, they are removed from the free particle population,
also at a rate of κV S/N . Finally, molecular decay and immunologically mediated death of virions
occurs at the rate ω.
The system above is mathematically difficult, not only due to its nonlinearities, but more
importantly, because it is not C1 at the origin. This can cause interesting dynamical behaviour
[7,18,32]. It is natural to extend the system by letting the right-hand sides of Equations (8)–
(11) equal zero when (Q, S, I, V ) = (0, 0, 0, 0). In the extended system, the origin is the only
equilibrium point, but since the system is not C1 at the origin, the system cannot be linearized
there and local stability cannot be determined. For this reason, we employ numerical simulations
to determine when virotherapy can act as a successful treatment, which is represented by a switch
from the exponential tumour growth to a stable cancer-free state (Figure 2).
2.2.2. Delay case
Finally, as in Section 2.1.2, we extend our model to include the minimum time that a cell spends
in the active phases of the cell cycle. In a similar fashion to our DDE model for tumour growth,
we include a holding compartment in which cells committed to the active phases of the cell cycle
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Figure 2. Tumour growth in time. Left: uncontrolled tumour growth in the absence of therapy. Middle: growing oscilla-
tory behaviour of solutions when virus-cell contact is modelled through mass action. Right: complete tumour elimination;
virus-cell contact is modelled through ratio dependence. Parameter values: a1 = 0.9, a2 = 0.6, d1 = 0.00001, κ¯ = 0.001,
κ = 1, δ = 1.119, ω = 0.3, and α = 3.
must reside for a minimum time τ . Owing to the more complex structure of these interactions,
we write the full model as a system of four ODEs and one age-structured PDE as follows:
dQ
dt
= 2Sˆ(τ, t) − a1Q − d1Q, (12)
dS
dt
= a1Q − a2S − d2S − κ V S
N
, (13)
∂Sˆ
∂t
+ ∂Sˆ
∂x
= −d3Sˆ − κ V Sˆ
N
, (14)
dI
dt
= −δI + κ V S + V S¯
N
, (15)
dV
dt
= αI − ωV − κ V S + V S¯
N
, (16)
where S¯(t) = ∫ τ0 Sˆ(x, t) dx, N(t) = Q(t) + S(t) + S¯(t) + I (t) + V (t), and the boundary con-
dition is given by
Sˆ(0, t) = a2S(t).
Sˆ is a function of two variables: t–time, and x–the length of time already spent in the cell cycle.
Note that the PDE now accounts for the loss of susceptible cells in the delay period. For biological
relevance, the initial conditions, Q(0), S(0), Sˆ(x, 0), I (0) and V (0), are all assumed to be non-
negative. To extend the model to the origin, when N = 0, we let the right-hand sides of Equations
(12)–(16) equal zero. Note that the system (12)–(16) reduces to (8)–(11) when τ = 0.
If we remove virotherapy, and assume that, for 0 ≤ x ≤ τ , Sˆ(x, 0) = a2φs(−x) e−d3x then this
system acts like Equations (3)–(5). With I and V removed, Sˆ can be found using the method of
characteristics,
Sˆ(x, t) = Sˆ(0, t − x) e−d3x.
We can then find S¯(t) noting that Sˆ(0, t − x) = a2S(t − x),
S¯(t) =
∫ τ
0
Sˆ(x, t) dx =
∫ τ
0
Sˆ(0, t − x) e−d3x dx
=
∫ τ
0
a2S(t − x) e−d3x dx
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=
∫ t
t−τ
a2S(u) e
−d3(t−u) du
= a2 e−d3t
∫ t
t−τ
ed3(u)S(u) du.
This is the same as the solution for the virus-free system, Equation (6).
Next we show that solutions remain non-negative.
Theorem 2.5 Assume thatQ(0), S(0), Sˆ(x, 0), I (0) andV (0) are non-negative. Then, solutions
of the system (12)–(16) are non-negative for t ≥ 0.
Proof If Q(0) = S(0) = Sˆ(x, 0) = Sˆ(0, t) = I (0) = V (0) = 0, then by definition Q(t) =
S(t) = Sˆ(x, t) = I (t) = V (t) = 0 and we are at equilibrium.
Otherwise by assumption, at t = 0, all compartments are greater than or equal to zero and
N(0) > 0. In this case, assume towards a contradiction that
t0 = inf
t>0
{t | Q(t) < 0, S(t) < 0, S¯(t) < 0, I (t) < 0 or V (t) < 0},
with t0 < ∞.
Next, let W = I + V and first assume that ω ≥ δ. Then
W ′ = −ωW + (α − δ + ω)I.
If f (t) = (α − δ + ω)I , then f (t) ≥ 0 for t ∈ [0, t0]. Second, assume that ω < δ. Then
W ′ = −δW + αI + (δ − ω)V.
If f (t) = αI + (δ − ω)V , then f (t) ≥ 0 for t ∈ [0, t0]. In general,
W ′ = −c1W + f (t), (17)
for some c1 > 0 ∈ R and with f (t) ≥ 0 for t ∈ [0, t0]. The solution of Equation (17) is
W(t) = W(0) e−c1t + e−c1t
∫ t
0
ec1ξ f (ξ) dξ.
If W(0) = 0, the system reduces to the model with no treatment. Otherwise, because W(0) > 0
and f (t) ≥ 0, W(t) > 0 for t ∈ [0, t0]. Since W(t0) > 0, N(t0) > 0. With N(t0) > 0, we can
now show that all compartments stay non-negative.
We begin with the age-structured PDE, Equation (14), and show that Sˆ(τ, t) ≥ 0 for t ∈ [0, t0 +
η), where η = min{, τ }. For each ζ ∈ R, define
S∗ζ (T ) = Sˆ(ζ + T , T ).
We are going to find solutions along the characteristic lines, x = ζ + T with t = T . Then,
dS∗ζ
dT
= ∂Sˆ
∂x
+ ∂Sˆ
∂t
and
(S∗ζ )
′ = −d3S∗ζ − κ
V S∗ζ
N
.
For each ζ , Equation (14) has now been converted into an ODE.
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Since t = T ,
S∗
′
ζ (t) = −d3S∗ζ (t) − κ
V (t)S∗ζ (t)
N(t)
.
Letting g(t) = d3 + κV (t)/N(t), we obtain
S∗
′
ζ (t) = −g(t)S∗ζ (t). (18)
Replacing Equation (14) with Equation (18), we have a system of ODE’s along each characteristic
line. From the form of the system of equations, and the non-negativity of the initial conditions
assumption, t0 > 0.
Since N(t0) > 0, then the ODE system is well posed and a solution exists on an interval
(t0 − , t0 + ). Moreover, by continuity, we may assume N(t) > 0 for t ∈ (t0 − , t0 + ).
Then solutions of Equation (18) along the characteristic lines x = ζ + t are
S∗ζ (t) = S∗ζ (0) e−
∫ t
0 g(u) du.
Each characteristic line in the x − t plane intersects either the non-negativex-axis or the positive
t-axis. If ζ ≥ 0, then the characteristic line intersects the non-negative x-axis and S∗ζ (0) = Sˆ(ζ, 0),
which is non-negative by assumption. Otherwise, ζ < 0, the characteristic line intersects the
positive t-axis at −ζ , and S∗ζ (0) = Sˆ(0,−ζ ) = a2S(−ζ ). By the definition of t0, we know that
S(−ζ ) is non-negative when −ζ ∈ [0, t0]. Thus, S∗ζ (0) ≥ 0 for each characteristic line which
intersects the positive t-axis at or below t0, (ζ ≥ −t0).
Since g(t) is bounded (0 ≤ g(t) ≤ d3 + κ) and S∗ζ (0) ≥ 0 for ζ ≥ −t0, on the corresponding
characteristic lines S∗ζ (t) will remain non-negative for as long as the solution exists. Therefore,
Sˆ(τ, t) will remain non-negative as well, for t ∈ (t0 − η, t0 + η) where η = min{, τ }. η is defined
this way to ensure that solutions lie on the proper characteristic lines and that solutions exist.
Next, we evaluate Equations (12)–(16), excluding the PDE. Each of the four equations is of the
form B ′(t) = A(t) − r(t)B(t), and B = Q,S, I , or V . Each equation has a solution of the form
B(t) = B(0) e−
∫ t
0 r(s) ds +
∫ t
0
e−
∫ t
ξ
r(s) ds
A(ξ) dξ,
where B is either Q, S, I or V . For Equation (12), A(t) = 2Sˆ(τ, t). We know Sˆ(τ, t) is greater
than or equal to zero for t ∈ [0, t0 + η), from the earlier characteristics argument. By assumption,
Q(0) ≥ 0 and we see that Q(t) ≥ 0 for t ∈ (t0 − η, t0 + η). For Equation (13), A(t) = a1Q(t),
so by similar reasoning, S(t) ≥ 0 for t ∈ (t0 − η, t0 + η). Since S(t) ≥ 0 for t ∈ (t0 − η, t0 + η),
S∗ζ (0) ≥ 0 for characteristic lines intersecting the t-axis up to t0 + η. So, Sˆ(x, t) ≥ 0 for t ∈
(t0 − η, t0 + η), and therefore so is S¯(t). Finally, since Q,S, Sˆ ≥ 0, using the same arguments
that were used to explain non-negativity of solutions in Section 2.1.2, solutions cannot leave the
positive quadrant of the I–V plane and I and V will remain non-negative for t ∈ (t0 − η, t0 + η).
We have shown that all compartments remain non-negative for t ∈ (t0 − η, t0 + η). This
contradicts the definition of t0. We conclude that solutions remain non-negative for all time. 
3. Numerical results
3.1. Parameter sensitivity analysis
To study the effects of variations in parameters on model behaviour, we use the Latin hypercube
sampling (LHS) [17]. Such a study is useful for statistically determining which parameters are
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Table 1. Table of parameters varied in LHS simulations of the full model, given by Equations (12)–(16).
Parameter Description Range Reference SROC p-value
a1 Quiescent cell entrance into active phases (day−1) 0.9 ± 50% [16] −0.2262 5 × 10−13
a2 Active cell entrance into quiescence (day−1) 0.6 ± 50% [16] 0.1125 0.0004
d1 Quiescent cell death (day−1) 1 × 10−5 ± 50% [16] 0.0092 0.7724
d2 Active cell death (day−1) 0.15 ± 50% [16] −0.0419 0.1852
α Virion production (day−1) 3 ± 50% Variable −0.1391 1 × 10−5
δ Infected cell elimination (day−1) 1.119 ± 50% [3] 0.0065 0.8379
ω Free virion decay (day−1) 0.3 ± 50% [3] 0.0267 0.3987
τ Minimum duration of active phases (day) [0, 3] Variable −0.0633 0.0455
κ Kinetic coefficient (day−1) [0, 5] Variable −0.3610 4 × 10−32
Notes: Parameters are varied around their estimated values, which were obtained from the references cited in the fourth column. The
third column reports SROCs between randomized parameter values and the resulting cancer concentration at time t = 100 days. For all
simulations, it was assumed that d3 = d2.
most dynamically influential. LHS involves numerically solving the system of equations multiple
times with randomly sampled parameter values. The samples are chosen such that each parameter
is well distributed over its range of admissible values.
In this study, we conduct 1000 LHS simulations of the full model, given by Equations (12)–
(16), and vary all model parameters according to a uniform distribution over the ranges shown in
Table 1. For each simulation, we measure the tumour burden given byQ + S + S¯ + I to determine
whether or not virotherapy is able to control the growth of the tumour over this time frame. To
assess the influence of each parameter, we calculate the Spearman rank-order correlation (SROC)
of each parameter and the tumour burden at 100 days after the start of treatment.
From the results displayed in Table 1, we see that the tumour burden (measured at time t = 100
days) is most negatively correlated with the following parameters: a1 – the rate at which quiescent
cells enter the active phase, α – the rate at which virions are produced from the lysis of infected
cells, and κ – the kinetic coefficient that governs the rate of interaction between virions and cells.
The tumour burden is also significantly negatively correlated with τ – the minimum duration of
the active phases of the cell cycle. These results imply that cells which spend more time in active
phases of the cell cycle are more susceptible to the effects of virotherapy. In addition, viruses that
produce more virions and infect cells at a faster rate tend to drive the cancer level lower.
On the other hand, the tumour burden is strongly positively correlated with a2, the rate at which
active cells enter quiescence. This result complements the strong negative correlation with a1
because it implies that cells that are only active for a brief period of time before returning to
quiescence render themselves less susceptible to virotherapy. The remaining parameters, d1, d2,
δ, and ω, pertain to death and decay rates of cells and virions and have little correlation with the
tumour burden.
These results imply that from a treatment perspective, it is strategic to combine a strong virus
therapeutic with a drug that prolongs the progression of cancer cells through the active cell cycle.
We direct the reader to the discussion section for commentary on synergy between cell cycle
altering drugs and VSV, and how this interaction can be incorporated into our model.
3.2. Therapy trajectories and dual parameter analysis
3.2.1. Non-delay case
Figure 2 shows three plots: the plot on the left displays unabated tumour growth over time. The
plot on the right exhibits the effect of VSV treatment on tumour growth over time. Essentially,
the untreated tumour grows exponentially (Figure 2, left). However, after treatment with VSV,
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Figure 3. Stability map for parameters governing viral reproduction (α) and contact (κ). Other parameter values are the
same as in Figure 2.
the tumour is eliminated over time, and the solution approaches the CFE (Figure 2, right). If
transmission were modelled with mass action instead of ratio dependence, the solution would
oscillate indefinitely (Figure 2, middle).
Two parameters that are strongly correlated with the effectiveness ofVSV treatment are α and κ .
As α increases, viral reproduction increases, and more virions are released by each cell that is
infected and lysed. Increasing the amount of viral particles increases the likelihood of virus–cell
contact, resulting in a more effective treatment. As κ increases, the likelihood that any susceptible
cell will become infected increases, also resulting in more effective therapy. Figure 3 shows how
the two parameters interact to either result in stability or instability of the CFE. Interestingly,
as α decreases, the increase in the transmission rate needed to fully remove the tumour grows
exponentially. As α decreases below 2, κ becomes prohibitively large, rendering the treatment
ineffective, even if it were possible to affect the transmission rate. The same statement can be
made for low values of κ . As the transmission rate becomes small, the viral reproduction rate
needed to wipe out the tumour becomes unreasonably large. Therefore, VSV must reproduce at
a sufficient rate and be reasonably transmissible for the treatment to remove the entire tumour
population.
3.2.2. Delay case
Figure 4 illustrates how the delay value, or the minimum duration of the susceptible state, can
increase the efficacy of the virus. In the left panel, the delay is considered without VSV treatment.
Under these parameters, the tumour grows exponentially. In the middle panel, using the same
parameters for tumour growth, the tumour is treated with VSV, but the delay is not taken into
account. Again, the tumour grows exponentially. However, once the time delay is included, VSV
successfully eliminates the tumour (right panel), demonstrating how the delay and the treatment
interact, leading to successful eradication of the tumour.
Next, we study how three parameters determining the efficacy of VSV treatment, α, κ , and
τ , interact (Figure 5). First, the stability of the CFE, while varying α and κ , with τ = 1 day is
considered (Figure 5, left). The rest of the parameter values are the same as those used in the
study of the non-delay model. The parameters qualitatively interact in the same manner as in the
non-delay model, but the curve is shifted downward and to the left, showing that, due to the delay,
the treatment is effective for a wider range of both α and κ values. Next, α and τ are varied, while
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Figure 4. Left: uncontrolled tumour growth (in the absence of virotherapy) under prolonged cell cycle progression
(τ = 0.5). Middle: when κ = 0.8, virotherapy treatment fails; minimum cell cycle time course is not accounted for.
Right: when κ = 0.8, virotherapy with a minimum cycling time (τ = 0.5) results in a stable cancer-free state. All other
parameter values are the same as in Figure 2.
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Figure 5. α, κ , and τ are varied, two at a time. For small α and κ , a delay value (τ ) beyond a certain threshold will ensure
stability of the origin. Parameter values if not varied: a1 = 0.9, a2 = 0.6, d1 = 0.00001, δ = 1.119, ω = 0.3, α = 1.5,
κ = 1, and τ = 1.
keeping κ = 1 (Figure 5, middle). The curve plateaus at the maximum value on the left. The
minimum value of τ needed for stability is determined in Theorem 2.2, and is not dependent on α
or κ . As α increases, the length of τ necessary to cause stability, decreases and approaches zero as
we reach the value of α necessary to cause stability without the delay (shown in the corresponding
picture for the non-delay model). Finally, κ and τ are varied, while keeping α = 1.5 (Figure 5,
right). The results are qualitatively similar to varying α and τ , except scaled.
4. Discussion
It was reported in 1904 that a patient’s cancer was driven into remission due to a viral infection [12].
Over a century later, a complete understanding of the underlying dynamics of the viral treatment
of tumours is still lacking, but some determinants of successful treatment have been uncovered.
For example, the success of virotherapy is heavily dependent on the particular virus chosen to
treat the tumour cells of interest. VSV has demonstrated anti-tumour efficacy in a large panel of
human tumour cell lines. Although VSV treats many types of tumours, experimental observations
in leukemic T-lymphocytes suggest that VSV does not kill non-proliferating tumour cells [19].
Seeking a better understanding of the dynamics of cell cycle-dependent oncolytic viruses, we have
developed a custom-tailored mathematical model for treatment with the oncolytic VSV therapeu-
tic, which captures its cell cycle-specific action. The model consists of a system of differential
equations, which include a representation of the non-quiescent phases of the cell cycle as a process
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with a minimum biological time course. We found that the parameters governing virotherapy
treatment, as well as the delay, affect the global asymptotic behaviour of our model; biologi-
cally, initiation of therapy and cell cycle-specific effects both impact the long-term behaviour of
the tumour.
We began with a framework for studying simple tumour growth with a seed model containing
compartments for resting and proliferating cells. Linear systems analysis yielded the expected
determinants of tumour growth and remission, which depend solely on cell transfer and death
rates. When we extended the model to account for the minimum biological time course of the
phases of the cell cycle leading to and including mitosis, we arrived at a three-dimensional system
of DDEs. In the context of the cell cycle, the delay value, τ , is the minimum amount of time
tumour cells must spend in the non-quiescent phases of the cell cycle. We found that for a given
set of model parameters, there exists a minimum value of τ that will drive the system towards a
globally stable cancer-free state. Furthermore, this threshold value can be calculated in terms of
the growth and death rates of tumour populations.
From the original model of tumour growth without the delay, we introduced virotherapy
treatment by including two additional compartments: infected cells and free virions. Virus-cell
contact and virus production, occurring via the lytic cycle, were included in the model. These
kinetics are modelled through the ratio-dependent contact between free virions and tumour cells.
Some models of virotherapy have utilized mass action kinetics to model virus–cell contact [3,30].
While mass action permits exact linear systems analysis, it yields a model in which therapy does
not impact the stability of the CFE. This result does not completely reveal the underlying strength
of virotherapy that has been demonstrated in many experiments: viral injections can indeed yield
tumour-free states. Our model complements these experimental results; the initiation of virother-
apy treatment in our model can drive the system towards the CFE. In addition, through our
five-dimensional age-structured model, we studied how the parameters that govern the lytic cycle
operate together, leading to tumour elimination. As any such parameter becomes small, successful
therapy becomes unattainable, as exponential growth in the other parameter is needed.
In our full model, we included a holding state for cells which enter the active stages of the
cell cycle, as developed in our three-dimensional delayed model of tumour growth but this time
using an age-structured PDE model. The holding state allows us to properly account for cell
death and viral infection over the length of the delay, while also guaranteeing non-negativity of
solutions. For parameters producing therapeutic failure (exponential tumour growth), a cancer-
free state can be attained for combinations of treatment parameters and the delay value. Parameter
sensitivity analysis illustrated that the rate of intracellular viral replication, α, the coefficient for
virus–cell contact, κ , the rate of entry into the susceptible phase from quiescence, a1, the rate of
entry into quiescence from the susceptible phase, a2, and the time delay, τ , substantially impact
model behaviour. Sampling of two-dimensional parameter space demonstrated that the values
of α, κ , and τ must be sufficiently large to ensure stability of the CFE. Therefore, the model
demonstrates the importance of abundant virus–cell fusion, rapid replication, and prolonged cell
cycle progression. Owing to the presence of a broadly neutralizing immune response after initial
use of VSV, it is essential to optimize the aforementioned factors in order to maximize the impact
of a single treatment [6].
The interaction between the virus therapeutic, cancerous cell populations, and their environment
is complex. Our model simplifies many facets of this system, while retaining features which reveal
dynamic behaviour. For example, we represent tumour and virion populations as functions of time.
In reality, tumours are spatially complex entities with elaborate growth patterns and vasculature.
Also, viral particle reproduction and flow within a tumour are not necessarily uniform. Although
our model does not account for these multi-scale biological features, we find that it functions as a
suitable framework for the holistic study of virus and cell population dynamics. It is also a sound
baseline model, to which other important physical features may be added. For example, our model
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can be modified to explore the effects of radiotherapy or chemotherapy coupled with virotherapy
treatment. Of particular interest is the synergistic relationship between VSV and chemotherapy
agents such as aphidicolin and paclitaxel [19]. These drugs arrest tumour cells during the active
phases of the cell cycle, increasing the probability of successful VSV attack over the entire tumour
population [19]. In the context of our model, this can be interpreted as an increased delay value,
yielding less stringent constraints on other parameters of the model for the achievement of a
cancer-free state. Overall, while we present a simplified representation of virotherapy within a
human host, our model is robust and adaptable.
There is visible progress in the development and testing of oncolytic virus therapeutics. A large
body of theoretical, experimental and clinical work has been initiated in the past several years.
Notably, several ground-breaking Phase III trials have begun. Although therapeutic develop-
ment strongly depends on animal models and tests on human subjects, mathematical modelling
navigates ground that is experimentally inaccessible. Specifically, mathematical models such
as ours can pinpoint the causes of therapeutic stagnation or failure. Such insights comple-
ment the efforts of physicians and experimental scientists in their development of novel cancer
therapies.
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